AstraZeneca to deliver 500,000 more doses of AZD7442 to US
The UK’s Cambridge-based biopharma company AstraZeneca will be delivering 500,000 more doses of AZD7442 to the US after having modified an existing agreement with the US Government.
The UK’s Cambridge-based biopharma company AstraZeneca will be delivering 500,000 more doses of AZD7442 to the US after having modified an existing agreement with the US Government.
The U.S. Food and Drug Administration (FDA) has approved Emergency Use Authorization (EUA) for investigational bamlanivimab and etesevimab as a combination therapy for the treatment of mild to moderate Covid-19 patients.
International PCOS Consortium has carried out a study to determine the common genetic architecture for different diagnostic criteria that are employed to describe polycystic ovary syndrome (PCOS).